TY - JOUR T1 - Gender Affirming Hormone Therapy induces specific DNA methylation changes in blood JF - medRxiv DO - 10.1101/2021.07.05.21260016 SP - 2021.07.05.21260016 AU - Rebecca Shepherd AU - Ingrid Bretherton AU - Ken Pang AU - Anna Czajko AU - Bowon Kim AU - Amanda Vlahos AU - Jeffrey D. Zajac AU - Richard Saffery AU - Ada Cheung AU - Boris Novakovic Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/06/2021.07.05.21260016.abstract N2 - DNA methylation is an epigenetic mark that is influenced by underlying genetic profile, environment, and aging. It also plays a key role in female-specific X-chromosome silencing in mammals. In addition to X-linked DNA methylation, sex-specific methylation patterns are widespread across autosomal chromosomes and can be present from birth or arise over time. In individuals where gender identity and sex assigned at birth are markedly and consistently incongruent, as in the case of transgender people, feminization or masculinization may be sought through gender affirming hormone therapy (GAHT). In this study we profiled genome-wide DNA methylation in blood of transgender women and transgender men, before and during GAHT (6 months and 12 months into hormone treatment). We identified several thousand differentially methylated CpG sites (DMPs) in both people undergoing feminizing and masculinizing hormone therapy, the vast majority of which were progressive changes over time. Sex-specific DNA methylation patterns established in early development are largely refractory to change in association with GAHT. The small number of sex-DMPs that were affected by GAHT were those that become sex-specific during the lifetime, known as sex-and-age DMPs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by an NHMRC (Australia) Investigator Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Austin Health Human Research Ethics Committee (HREC/17/Austin/74)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe genome-wide DNA methylation dataset produced in this study is available at Gene Expression Omnibus GSE176394 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176394 ER -